60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Sees Significant Growth in Short Interest

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 130,700 shares, a growth of 95.1% from the March 31st total of 67,000 shares. Based on an average daily volume of 335,700 shares, the short-interest ratio is currently 0.4 days. Currently, 1.5% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, April 3rd.

60 Degrees Pharmaceuticals Stock Performance

SXTP remained flat at $0.24 during midday trading on Friday. 94,376 shares of the company’s stock were exchanged, compared to its average volume of 94,055. The company’s fifty day moving average price is $0.27 and its 200-day moving average price is $0.55. 60 Degrees Pharmaceuticals has a one year low of $0.22 and a one year high of $8.65.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its earnings results on Monday, April 1st. The company reported ($0.44) earnings per share (EPS) for the quarter. The business had revenue of ($0.10) million for the quarter, compared to the consensus estimate of $0.06 million. As a group, analysts forecast that 60 Degrees Pharmaceuticals will post -0.29 EPS for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.